Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ

被引：0
|
作者：
Manier, Salomon [1 ]
Dimopoulos, Meletios-Athanasios [2 ]
Leleu, Xavier [3 ]
Moreau, Philippe [4 ]
Cavo, Michele [5 ]
Goldschmidt, Hartmut [6 ]
Orlowski, Robert Z. [7 ]
Tron, Muriel [8 ]
Tekle, Christina [8 ]
Bregeault, Marie-France [9 ]
Shafer, Andrea [8 ]
Beksac, Meral [10 ]
Facon, Thierry [11 ]
机构：
[1] Univ Hosp Ctr Lille, Dept Hematol, Lille, France
[2] Univ Athens, Sch Med, Athens, Greece
[3] CHU Poitiers, Poitiers, France
[4] Univ Hosp Hotel Dieu, Hematol Dept, Paris, France
[5] Univ Bologna, IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy
[6] Univ Hosp Heidelberg, Dept Internal Med 5, GMMG Study Grp, Heidelberg, Germany
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Sanofi, Baltimore, MD USA
[9] Sanofi, R&D, Vitry Sur Seine, France
[10] Istinye Univ, Ankara Liv Hosp, Ankara, Turkiye
[11] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-426
引用
收藏
页码：S290 / S291
页数：2
相关论文
共 50 条
  • [11] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Venner, Christopher P.
    Bahlis, Nizar J.
    Offner, Fritz
    White, Darrell J.
    Karlin, Lionel
    Benboubker, Lotfi
    Rigaudeau, Sophie
    Rodon, Philippe
    Voog, Eric
    Yoon, Sung-Soo
    Suzuki, Kenshi
    Shibayama, Hirohiko
    Zhang, Xiaoquan
    Twumasi-Ankrah, Philip
    Yung, Godwin
    Rifkin, Robert M.
    Moreau, Philippe
    Lonial, Sagar
    Kumar, Shaji K.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    BLOOD, 2021, 137 (26) : 3616 - 3628
  • [12] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
    Mateos, Maria-Victoria
    Dimopoulos, Meletios A.
    Cavo, Michele
    Suzuki, Kenshi
    Knop, Stefan
    Doyen, Chantal
    Lucio, Paulo
    Nagy, Zsolt
    Pour, Ludek
    Grosicki, Sebastian
    Crepaldi, Andre
    Liberati, Anna Marina
    Campbell, Philip
    Yoon, Sung-Soo
    Iosava, Genadi
    Fujisaki, Tomoaki
    Garg, Mamta
    Iida, Shinsuke
    Blade, Joan
    Ukropec, Jon
    Pei, Huiling
    Van Rampelbergh, Rian
    Kudva, Anupa
    Qi, Ming
    San-Miguel, Jesus
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 785 - 798
  • [13] Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
    Leleu, Xavier
    Hulin, Cyrille
    Lambert, Jerome
    Bobin, Arthur
    Perrot, Aurore
    Karlin, Lionel
    Roussel, Murielle
    Montes, Lydia
    Cherel, Brieuc
    Chalopin, Thomas
    Slama, Borhane
    Chretien, Marie-Lorraine
    Laribi, Kamel
    Dingremont, Claire
    Roul, Christophe
    Mariette, Clara
    Rigaudeau, Sophie
    Calmettes, Claire
    Dib, Mamoun
    Tiab, Mourad
    Vincent, Laure
    Delaunay, Jacques
    Santagostino, Alberto
    Macro, Margaret
    Bourgeois, Emmanuelle
    Orsini-Piocelle, Frederique
    Gay, Julie
    Bareau, Benoit
    Bigot, Noemie
    Vergez, Francois
    Lebreton, Pierre
    Tabrizi, Reza
    Waultier-Rascalou, Agathe
    Frenzel, Laurent
    Le Calloch, Ronan
    Chalayer, Emilie
    Braun, Thorsten
    Lachenal, Florence
    Corm, Selim
    Kennel, Celine
    Belkhir, Rakiba
    Blade, Jean-Sebastien
    Joly, Bertrand
    Richez-Olivier, Valentine
    Gardeney, Helene
    Demarquette, Helene
    Robu-Cretu, Daniela
    Garderet, Laurent
    Newinger-Porte, Muriel
    Kasmi, Amine
    NATURE MEDICINE, 2024, 30 (08) : 2235 - 2241
  • [14] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
    O'Donnell, Elizabeth
    Laubach, Jacob P.
    Yee, Andrew J.
    Huff, Carol Ann
    Basile, Frank
    Wade, Philip M.
    Paba-Prada, Claudia E.
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Couture, Nicole
    Doherty, Lauren
    Lyons, Hannah
    English, Caroline
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur
    BLOOD, 2014, 124 (21)
  • [15] Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
    Ocio, Enrique M. M.
    Bringhen, Sara
    Martinez-Lopez, Joaquin
    San-Miguel, Jesus
    Oliva, Stefania
    Rodriguez-Otero, Paula
    Le Roux, Nadia
    Dong, Yvonne
    Doroumian, Severine
    Mace, Sandrine
    Mateos, Maria-Victoria
    HEMASPHERE, 2023, 7 (02):
  • [16] Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
    Usmani, Saad Z.
    Facon, Thierry
    Hungria, Vania
    Bahlis, Nizar J.
    Venner, Christopher P.
    Braunstein, Marc
    Pour, Ludek
    Marti, Josep
    Basu, Supratik
    Cohen, Yael C.
    Matsumoto, Morio
    Suzuki, Kenshi
    Hulin, Cyrille
    Grosicki, Sebastian
    Legiec, Wojciech
    Beksac, Meral
    Maiolino, Angelo
    Liu, Weiping
    Wang, Jianping
    Krevvata, Maria
    Lopez-Masi, Lorena
    Carey, Jodi
    Rowe, Melissa
    Carson, Robin
    Zweegman, Sonja
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S288 - S289
  • [17] Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
    Usmani, S. Z.
    Cavenagh, J. D.
    Belch, A. R.
    Hulin, C.
    Basu, S.
    White, D.
    Nooka, A.
    Ervin-Haynes, A.
    Yiu, W.
    Nagarwala, Y.
    Berger, A.
    Pelligra, C. G.
    Guo, S.
    Binder, G.
    Gibson, C. J.
    Facon, T.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (03) : 243 - 258
  • [18] Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study
    Kumar, Shaji K.
    Facon, Thierry
    Usmani, Saad Z.
    Plesner, Torben
    Orlowski, Robert Z.
    Touzeau, Cyrille
    Basu, Supratik
    Bahlis, Nizar J.
    Goldschmidt, Hartmut
    O'Dwyer, Michael E.
    Venner, Christopher P.
    Weisel, Katja
    Hulin, Cyrille
    Karlin, Lionel
    Preis, Meir
    Broyl, Annemiek
    Renwick, William
    Hansson, Markus
    Krevvata, Maria
    Wang, Jianping
    Van Rampelbergh, Rian
    Ukropec, Jon
    Uhlar, Clarissa M.
    Kobos, Rachel
    Perrot, Aurore
    BLOOD, 2020, 136
  • [19] Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant
    Ocio, Enrique M.
    Rodriguez Otero, Paula
    Bringhen, Sara
    Oliva, Stefania
    Nogai, Axel
    Attal, Michel
    Moreau, Philippe
    Kanagavel, Dheepak
    Fitzmaurice, Thomas F.
    Wu, Junlong
    Martinez Lopez, Joaquin
    BLOOD, 2018, 132
  • [20] Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment
    Saeed, Nabiha
    Khan, Zurrya
    Jehanzeb, Hamzah
    Shaikh, Taha
    Shaikh, Usman
    Adil, Salman N.
    Madni, Varisha
    Fatima, Hania
    Abiha, Umm E.
    Ali, Natasha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
12345